An IPO arrives with a story: get in at the beginning, before the crowd, like the early investors in Amazon or Google. The data tells a colder story. Jay Ritter, the University of Florida professor who has tracked every US IPO for decades, finds that newly listed companies have, on average, underperformed comparable stocks over the three years after listing. The exciting first-day pop and the disappointing multi-year aftermath are both real — and both are produced by the same machinery. Understanding that machinery tells you when an IPO deserves your money and, more often, when it deserves your patience.
An IPO Is a Sale, and You Are Not the Seller
Start with who controls the timing. A company going public chooses its moment — and it chooses when conditions flatter it: revenue accelerating, the market hot, the sector in fashion. Insiders and early venture investors are, at least partly, selling. That creates a structural information asymmetry: the people who know the business best picked this exact window to convert their shares into your cash. It does not make every IPO a trap, but it should set your prior. Nobody schedules their IPO for the moment their numbers look worst.
The First-Day Pop Is Not for You
The famous IPO "pop" — the stock leaping 30% on day one — is mostly an illusion of access. The pop is the gap between the offer price, available to institutions and favoured clients, and the open-market price where ordinary investors actually get to buy. Buying at the open means buying after the easy gain has been distributed to someone else, frequently at the day's emotional peak. The 2020-2021 IPO cohort made this brutal: many of the era's celebrated debuts traded below their first-day closing prices for years afterward, even when the offer-price buyers were still in profit.
Why the First Year Is Usually Rough
Three forces weigh on a new listing. Valuation: priced at peak enthusiasm by bankers paid to maximise proceeds, IPOs start expensive, and expensive starting points predict weak forward returns. Lockup expiry: insiders are typically barred from selling for about 180 days, after which a wall of shares can hit the market — a known, dated supply shock. And the reporting reality check: a few quarters as a public company replace the roadshow narrative with actual numbers, which is precisely when the 2021 class — Rivian, Robinhood, and many SPAC debuts among them — repriced 70-90% below their peaks. None of this requires the company to be bad; it requires only that the debut was priced for perfection.
The Honest Exceptions
The averages conceal real winners — buy-and-hold investors in the right IPO did extraordinarily well, and some businesses were obviously exceptional early. Meta fell roughly half below its 2012 offer price in its first months, then proved its mobile business and compounded for a decade. The pattern worth noticing: even many eventual winners offered a better entry after the IPO froth cleared than on day one. The market's judgment of a new listing in its first weeks is noise; its judgment after a few earnings reports is information. Waiting converts a story stock into a stock with a track record — usually at no premium for the delay.
A Sensible Playbook
Treat an IPO like any other stock, minus the urgency. Skip the first-day chase — the structural edge there belongs to others. Put genuinely interesting debuts on a watchlist and let two or three quarters of real reporting arrive, noting how the stock digests its lockup expiry. Read the prospectus with one question in mind: is this raise funding growth, or funding exits? Then value it against established peers as if the word "IPO" did not exist — because within a year, it won't. The ground floor is a marketing image; the data says the patient entrance is usually on the same floor, with a better view of the building.